All,
This week we will mark a milestone for Bioventus as we ring the closing bell at NASDAQ on Tuesday! Many members of our executive leadership team and executives representing each department at Bioventus will join me at the stock exchange as Bioventus memorializes being a public company (please note this is delayed from last year due to the pandemic). This is a celebration of the amazing and significant evolution of the company and in fact the timing is even better than last year as we can recognize the significant transition the company has made over the past couple of years!
NASDAQ has asked for a few words on the company and since most of you will not be able to be there for this particular event please find below some outtakes. I will use my couple of minutes to highlight our company, its history, our team, where we have come from and most importantly where we are going!
- Bioventus is not an overnight success story and in fact started about 20 years ago as a division of medical device company Smith & Nephew with a mission of improving patient lives through its Innovations for Active Healing. Our focus in helping orthopedic patients recover from pain and injury has grown into what is today a rapidly growing medical device organization with over $500M in revenue and significant EBITDA.
- Joining me today are members of our executive leadership team as well as leaders at Bioventus representing each department. They are all critical, passionate and humble leaders that have made a tremendous difference taking Bioventus to where it is today. At Bioventus we work at creating a cohesive executive leadership team where we work hard to drive alignment and ultimately make sure we are all pushing our business in the same direction with the same goals to optimize our productivity and increase the pace of our business.
- We have a broad based business, work with many physician specialty areas that prescribe our medical devices and use them to help patients spanning treatments for osteoarthritis pain, acute and chronic pain, healing of difficult fractures as well as wounds, supporting patients in their physical rehabilitation from neurological and orthopedic injuries and supply of medical devices used in surgery to treat degenerative spinal conditions.
- In 2022 Bioventus medical devices will be used around the world by our physician customers helping over 600,000 patients which is approximately one patient every 50 seconds.
- What has made Bioventus successful over these years is a culture focused on achieving superior Results while balancing that with a Caring environment focused on relationships of mutual trust and a focus on doing what is right for the patients we ultimately serve.
- We are now executing a strategy that has allowed the company to enter a new phase of growth in the past couple of years. As a public company our vision is consistent double digit growth in revenue and EBITDA as we take the company into a new level of expansion that will allow us to help more patients.
- As part of our effort for continuous improvement we have added Learning as a key attribute to our organizational culture.
- Bioventus will continue to excel because of its resilient focus on continuous improvement and learning during the times that things don’t go as well as planned. We are big enough to be relevant in our markets but small enough to be agile and evolve based on current or changing market conditions.
- Continuous improvement will be the hallmark of our success as we build our culture, organizational design and expanding product portfolio focused on Innovations for Active Healing to drive consistent double digit growth.
- We are focused on delivering outstanding results for all of our stakeholders in the quarters and years ahead and have key demographic trends of an aging population as a tailwind to our accelerated global growth in Medtech.
A special Thank You to all employees and leaders across our organization who have worked to put Bioventus on the map. Our best days are ahead of us!
Have a great week!